Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children

Clinics in Chest Medicine
H S SchaafKeertan Dheda

Abstract

Available data show that Africa, together with the Americas and western and central Europe, reported the lowest prevalence of multidrug-resistant tuberculosis (MDR-TB). However, sub-Saharan Africa has a high TB incidence and the highest human immunodeficiency virus (HIV) prevalence in the world, and because of the high number of TB cases, Africa still presents 14% of the global burden of new MDR-TB cases. Until recently, Africa and South America were deprived of second-line antituberculosis drugs, preventing the development of extensively drug-resistant TB (XDR-TB). Current efforts, introducing improved laboratory infrastructure and second-line TB treatment in resource-limited countries, need to be carried out with care to minimize the development of MDR/XDR-TB in these countries. Recent diagnostic developments now need evaluation and implementation in resource-limited areas, and delays in diagnosis also need to be addressed. Outcomes for MDR/XDR-TB have improved, but prevention of MDR/XDR-TB by early diagnosis and treatment, improvement of adherence, and proper infection control remains the mainstay for the future.

References

Jul 13, 2000·Lancet·A Van RieP D Van Helden
Mar 1, 2005·The Annals of Thoracic Surgery·Shin-ichi TakedaRyoji Maekura
May 24, 2005·The Journal of Infection·Bent von der LippeOddbjørn Brubakk
May 25, 2005·The Journal of Antimicrobial Chemotherapy·Jesús FortúnSantiago Moreno
Jun 1, 2005·Journal of Chemotherapy·S SulochanaC N Paramasivan
Jun 11, 2005·American Journal of Respiratory and Critical Care Medicine·Annelies van RieRobin M Warren
Feb 8, 2006·The Pediatric Infectious Disease Journal·Nesri PadayatchiRazia Bobat
Jun 3, 2006·Pediatrics·Peter C DrobacMercedes C Becerra
Jul 11, 2006·Acta Paediatrica·H Simon SchaafPeter R Donald
Jul 18, 2006·The Journal of Infectious Diseases·Matteo ZignolChristopher Dye
Jul 22, 2006·The Journal of Antimicrobial Chemotherapy·I-Nae ParkTae Sun Shim
Feb 13, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H S SchaafP R Donald
Jun 19, 2007·Paediatric Respiratory Reviews·Banu Rekha, Soumya Swaminathan
Aug 30, 2007·The Journal of Infectious Diseases·Charles D WellsKarin Weyer
Sep 1, 2007·The Journal of Antimicrobial Chemotherapy·Oluwabunmi Y SaliuRobert S Wallis
Jan 16, 2008·BMC Public Health·Dag Gundersen StorlaGunnar Aksel Bjune
Jan 19, 2008·American Journal of Respiratory and Critical Care Medicine·Marinus BarnardMarlein E Bosman
Feb 29, 2008·Journal of Clinical Microbiology·K G P HoekR M Warren
May 31, 2008·American Journal of Respiratory and Critical Care Medicine·Anton MakDick Menzies
Jul 10, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yong Soo KwonWon-Jung Koh
Aug 9, 2008·The New England Journal of Medicine·Carole D MitnickMercedes C Becerra
Aug 9, 2008·The New England Journal of Medicine·Edward D ChanMichael D Iseman
Aug 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·David W DowdySusan E Dorman
Aug 30, 2008·Journal of Clinical Microbiology·Matsie MphahleleHarleen M S Grewal
Sep 16, 2008·International Journal of Antimicrobial Agents·Hae-Seong NamTae Sun Shim
Sep 24, 2008·Seminars in Respiratory and Critical Care Medicine·Carole D MitnickSonya S Shin
Oct 14, 2008·The Journal of Infectious Diseases·Jason R AndrewsUNKNOWN Tugela Ferry Care and Research Collaboration
Nov 4, 2008·Current Opinion in Infectious Diseases·Edward D Chan, Michael D Iseman
Nov 8, 2008·The Lancet Infectious Diseases·Mandeep Jassal, William R Bishai
Nov 29, 2008·The New England Journal of Medicine·Keertan DhedaMotasim Badri

❮ Previous
Next ❯

Citations

Oct 1, 2011·Bulletin de la Société de pathologie exotique·O AbdelhadiB Heym
Dec 16, 2011·Bulletin de la Société de pathologie exotique·D MounguenguiP L'her
Apr 6, 2012·The Journal of Infectious Diseases·Alimuddin ZumlaRifat Atun
Feb 8, 2011·The Pediatric Infectious Disease Journal·Mona Al-DabbaghTobias R Kollmann
Sep 14, 2013·Journal of Postgraduate Medicine·M Dash
Aug 22, 2012·European Journal of Pediatrics·Aspasia KatragkouJohn Tsanakas
Jul 23, 2013·Journal of Pain and Symptom Management·Richard A PowellFaith N Mwangi-Powell
Dec 19, 2015·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Rohan MalikRicha Lal
Dec 22, 2010·Paediatric Respiratory Reviews·H Simon Schaaf, Ben J Marais
Aug 3, 2010·Infectious Disease Clinics of North America·Keertan DhedaMartin P Grobusch
Jun 16, 2010·Tropical Medicine & International Health : TM & IH·Giovanni Battista MiglioriAlimuddin Zumla
Jun 22, 2010·Tropical Medicine & International Health : TM & IH·W A HanekomA Whitelaw
Mar 5, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Christoph Lange, Toru Mori
Aug 8, 2015·African Journal of Primary Health Care & Family Medicine·Ntambwe Malangu, Omotayo D Adebanjo
May 11, 2015·The Lancet Infectious Diseases·Sharon NachmanCarol Worrell
Jul 2, 2011·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Viviana RitaccoSofia Samper
Apr 11, 2014·The Lancet. Respiratory Medicine·Keertan DhedaRobin Warren
Aug 28, 2010·The Lancet Infectious Diseases·José A CamineroGiovanni Battista Migliori
Mar 24, 2009·Tropical Medicine & International Health : TM & IH·Haileyesus GetahunPaul Nunn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.